Reply:

References

1. 1.↵
   2. Ramalho J,
   3. Semelka RC,
   4. Ramalho M, et al

   . Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 2015 Dec 10. [Epub ahead of print] doi:10.3174/ajnr.A4615 pmid:26659341

   Abstract/FREE Full Text
2. 2.↵
   2. Stojanov DA,
   3. Aracki-Trenkic A,
   4. Vojinovic S, et al

   . Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26:807–15 doi:10.1007/s00330-015-3879-9 pmid:26105022

   CrossRefPubMed
3. 3.↵
   2. Radbruch A,
   3. Weberling LD,
   4. Kieslich PJ, et al

   . High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol 2015;50:805–10 doi:10.1097/RLI.0000000000000227 pmid:26523910

   CrossRefPubMed
4. 4.↵
   2. Cao Y,
   3. Huang DQ,
   4. Shih G, et al

   . Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 2016;206:414–19 doi:10.2214/AJR.15.15327 pmid:26700156

   CrossRefPubMed
5. 5.↵
   2. Kanda T,
   3. Osawa M,
   4. Oba H, et al

   . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

   CrossRefPubMed
6. 6.↵
   2. Radbruch A,
   3. Weberling LD,
   4. Kieslich PJ, et al

   . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

   CrossRefPubMed
7. 7.↵
   2. Jost G,
   3. Lenhard DC,
   4. Sieber MA, et al

   . Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents. Invest Radiol 2016;51:83–89 doi:10.1097/RLI.0000000000000242 pmid:26606548

   CrossRefPubMed
8. 8.↵
   2. Robert P,
   3. Violas X,
   4. Grand S, et al

   . Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 2016;51:73–82 doi:10.1097/RLI.0000000000000241 pmid:26606549

   CrossRefPubMed
9. 9.↵
   2. Robert P,
   3. Lehericy S,
   4. Grand S, et al

   . T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 2015;50:473–80 doi:10.1097/RLI.0000000000000181 pmid:26107651

   CrossRefPubMed
10. 10.↵
    2. Kanda T,
    3. Fukusato T,
    4. Matsuda M, et al

    . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–32 doi:10.1148/radiol.2015142690 pmid:25942417

    CrossRefPubMed
11. 11.↵
    2. McDonald RJ,
    3. McDonald JS,
    4. Kallmes DF, et al

    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

    CrossRefPubMed